Understanding the United States Chronic Lymphocytic Leukemia (CLL) Patient Journey to Make Informed Business Decisions, Identify Opportunities, and Understand Potential Challenges
25 oct. 2024 04h07 HE
|
Research and Markets
Dublin, Oct. 25, 2024 (GLOBE NEWSWIRE) -- The "Chronic Lymphocytic Leukemia (CLL) in the United States: Understanding the CLL Patient Experience" report has been added to ResearchAndMarkets.com's...
Understanding the United States Chronic Myeloid Leukemia (CML) Patient Experience to Make Informed Business Decisions, Identify Opportunities, and Understand Potential Challenges
25 oct. 2024 04h06 HE
|
Research and Markets
Dublin, Oct. 25, 2024 (GLOBE NEWSWIRE) -- The "Chronic Myeloid Leukemia (CML) in the United States: Understanding the CML Patient Experience" report has been added to ResearchAndMarkets.com's...
United States Chronic Myeloid Leukemia (CML) Patient Quality of Life & Information-Seeking Behaviors Insights Report 2024
24 oct. 2024 04h25 HE
|
Research and Markets
Dublin, Oct. 24, 2024 (GLOBE NEWSWIRE) -- The "Chronic Myeloid Leukemia (CML) in the United States: Quality of Life & Information-Seeking Behaviors" report has been added to ...
Smart Immune détermine la dose recommandée de SMART101 pour ses essais cliniques en oncologie
23 oct. 2024 01h01 HE
|
Smart Immune
La phase I d'escalade de dose de ReSET-02 chez des adultes souffrant de cancers hématologiques est terminée.Le segment randomisé de la phase II de cet essai est en cours.Aucune toxicité limitant la...
Smart Immune Announces Recommended SMART101 Dose for Adult Cancer Proof-of-Concept Trials
23 oct. 2024 01h01 HE
|
Smart Immune
ReSET-02 dose escalation Phase I is completedPhase II PoC randomized segment is starting No dose-limiting toxicities, no safety or tolerability issuesThe highest dose is to be used in both...
NMDP℠ Raises $1.1 Million at Annual Gala Expanding Access to Life-Saving Cell Therapies
03 oct. 2024 09h00 HE
|
NMDP
NMDP, a global nonprofit leader in cell therapy, raised $1.1 million during its 17th annual fundraising gala expanding access to life-saving treatments.
Acute Myeloid Leukemia (AML) in the United States: Primary Insights Into the Patient Experience
26 sept. 2024 04h25 HE
|
Research and Markets
Dublin, Sept. 26, 2024 (GLOBE NEWSWIRE) -- The "Acute Myeloid Leukemia (AML) in the United States: A Review of 2023 - Key Insights into Treatment Awareness & Satisfaction" report has been added...
Chronic Lymphocytic Leukemia (CLL) in the United States: A Review of 2023 - Key Insights into Treatment Awareness & Satisfaction
26 sept. 2024 04h23 HE
|
Research and Markets
Dublin, Sept. 26, 2024 (GLOBE NEWSWIRE) -- The "Chronic Lymphocytic Leukemia (CLL) in the United States: A Review of 2023 - Key Insights into Treatment Awareness & Satisfaction" report has been...
U.S. Chronic Myeloid Leukemia (CML) Treatment Awareness & Satisfaction Report - What Medications Have Patients Discussed With Their HCP?
26 sept. 2024 04h21 HE
|
Research and Markets
Dublin, Sept. 26, 2024 (GLOBE NEWSWIRE) -- The "Chronic Myeloid Leukemia (CML) in the United States: A Review of 2023 - Key Insights into Treatment Awareness & Satisfaction" report has been...
U.S. Myelodysplastic Syndromes (MDS) Patient Insights Report: HCP Treatment Discussions, Treatment Satisfaction & Awareness, Clinical Trial Interest, and Much More
26 sept. 2024 04h20 HE
|
Research and Markets
Dublin, Sept. 26, 2024 (GLOBE NEWSWIRE) -- The "Myelodysplastic Syndromes (MDS) in the United States: A Review of 2023 - Key Insights into Treatment Awareness & Satisfaction" report has been...